Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

lilly_entrance_web

Eli Lilly’s Emgality approved in the US for episodic cluster headache

June 5, 2019
Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma

Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …

News
lilly_entrance_web

Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …

News
lilly_entrance_web

Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population

May 13, 2019
Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …

News
headquarters_3_web

Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

May 8, 2019
Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 3, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Gilead, autism, dementia, opioids, pharma

This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from …

News
lilly_building_with_american_flag_web

Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

April 26, 2019
Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …

News
lilly_building_with_american_flag_web

Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

March 13, 2019
Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …

News
diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …

News
lilly_building_with_american_flag_web

Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

February 5, 2019
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …

News

EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure

January 24, 2019
Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma

Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …

News
lilly_building_with_american_flag_web

Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma

January 21, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure

Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …

News

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …

News
lilly_building_with_american_flag_web

Eli Lilly to buy Loxo Oncology in deal worth $8 billion

January 7, 2019
Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine

US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …

News

Latest content

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

June 17, 2024

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024